Lumen Bioscience Raises $16M Series B Financing to Accelerate Clinical Development of Accessible Biologic Drugs

Sep 01, 2020•almost 5 years ago

Amount Raised

$16 Million

Round Type

series b

Seattle

Description

Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the closing of a $16 million Series B financing. The financing was co-led by new investor WestRiver Management and returning investor Bioeconomy Capital, with additional participation from existing investors Avista Development, Columbia Pacific, Lumen’s founders, and Seattle-area angels.

Company Information

Company

Lumen Bioscience

Location

Seattle, Washington, United States

About

Lumen Bioscience discovers, develops and manufactures biologic drugs and vaccine candidates for several prevalent, worldwide diseases—many of which currently lack any effective treatments. The company’s unique drug development and manufacturing platform offers the potential to transform the biologics industry through increased speed, mass-market scale and exponentially lower costs than current approaches. For more information, visit: www.lumen.bio.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech